From the Journals

Two popular screening tests for gestational diabetes clinically equivalent


 

FROM THE NEW ENGLAND JOURNAL OF MEDICINE

U.S. doctors unlikely to change behaviors

Most U.S. physicians favor the two-step method. This has been a huge controversy worldwide, with other countries pushing the United States to use the one-step method, Vincenzo Berghella, MD, a professor with Thomas Jefferson University, Philadelphia, said in an interview. “I expect this study will increase the divide between the U.S. and the rest of the world,” since U.S. physicians will see no benefit to the one-step method, and continue to use the two-step method.

Dr. Vincenzo Berghella is a professor at Thomas Jefferson University in Philadelphia

Dr. Vincenzo Berghella

It’s not surprising that GDM diagnosis incidence went up to 16.5% with the inclusion of the one-step test, compared with 8.5% with the two-step test, Dr. Berghella continued. What’s less clear, are the details of treatment among the 8% diagnosed to have GDM with the one-step test, but not the two-step test.

These women were likely to have milder degrees of insulin resistance or GDM. Dr. Berghella, who has advocated in the past for the one-step approach, said it would be important to find out if these women, who test positive at the one-step test but would test negative at the two-step test, were treated properly with diet, exercise, and possibly insulin or other hypoglycemic agents for their mild degree of insulin resistance. The researchers concluded that expanding the definition of GDM through the one-step test didn’t make a difference. However, “it’s not just the test that will make the difference in maternal and baby outcomes, but the aggressive management of diabetes with diet, exercise, and medications as needed once that test comes back abnormal,” he said.

The randomized trial was a massive undertaking, said Dr. Hillier.

“We are still evaluating our future plans,” she added. Forthcoming subgroup analyses from the trial could further help inform clinical practice guidelines.

Dr. Hillier received a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development to support this study. The investigators reported no potential conflict of interest relevant to this article.

Pages

Recommended Reading

New case suggestive of in utero SARS-CoV-2 transmission
MDedge Endocrinology
COVID-19 in pregnancy raises risk of preterm birth and severe disease
MDedge Endocrinology
Metformin improves most outcomes for T2D during pregnancy
MDedge Endocrinology
One in five gestational carriers do not meet ASRM criteria
MDedge Endocrinology
Microplastics permeate human placentas
MDedge Endocrinology
Higher dose maximizes effects of magnesium sulfate for obese women
MDedge Endocrinology
Severe maternal morbidity promotes long-term mortality
MDedge Endocrinology
Gestational diabetes carries CVD risk years later
MDedge Endocrinology
Algorithm trims time to treatment of acute hypertension in pregnancy
MDedge Endocrinology
Metformin tied to longer gestation in women with preterm preeclampsia
MDedge Endocrinology